ClinicalTrials.gg
CompletedNCT02263079Updated Aug 24, 2020Results posted

A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase

A Phase 3 interventional study of Entecavir and Lamivudine in Pediatric Immuno-Tolerant Chronic Hepatitis B, sponsored by Hoffmann-La Roche. Completed at 25 sites in 12 countries. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-08-24.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jun 2014, registered Oct 2014).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
3 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.

Enrollment
44th of 61
62 · median 109
Started
2014
with 1 other
Phase 3
13 of 64
none open now
Registered
44th of 64
by date
Lead sponsor
4 of 64
Hoffmann-La Roche

Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 44th largest by enrollment of the 61 interventional ones that give a count, is one of 2 that started in 2014, is one of 13 in phase 3, and was the 44th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About entecavir

entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 3 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing entecavir in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

This randomized, controlled, parallel group, open-label multicenter study will evaluate the efficacy and safety of a combination of pegylated interferon alfa-2A (Pegasys) plus lamivudine or entecavir compared with an untreated control group in participants with HBeAg positive CHB in the immune tolerant phase. NOTE: STUDY RECRUITMENT HAS BEEN TERMINATED

03

Conditions studied

  • Pediatric Immuno-Tolerant Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Positive for and HBeAg for more than 6 months prior to baseline
  • Detectable HBV-DNA (>20,000 IU/mL) as measured by polymerization chain reaction (PCR) or hybridization on at least 2 occasions at least one month apart with the latest determination obtained less than or equal to (\</=) 42 days prior to baseline
  • Compensated liver disease ( Class A clinical classification)
  • Either Liver performed within 2 years prior to baseline showing no or minimal fibrosis (Liver Biopsy Scores and stable normal levels (less than or equal to [ULN]) during the 6 months leading up to baseline (including two separate occasions at least 1 month apart over the 6 months prior to baseline). Screening ALT levels must be normal (\</= ULN) OR Stable normal ALT levels (\</= ULN), during the 1 year leading up to baseline (including three separate occasions at least 1 month apart over the 1 year prior to baseline) and no signs of hepatocellular carcinoma (HCC), advanced fibrosis/cirrhosis, or splenomegaly on liver abdominal ultrasound at screening. Screening ALT levels must be normal (\</= ULN)

Exclusion criteria

Exclusion Criteria:

  • Participants who have received drugs or licensed treatments with anti activity (Exception: Participants who have had a limited [\</= 7-day] course of acyclovir for herpetic lesions more than 1 month before the study baseline visit are not excluded)
  • Participants who have participated in any other clinical trial or who have received any investigational drug within 6 months prior to baseline
  • Known to interferon (IFN), pegylated interferon-alfa-2a or lamivudine or entecavir
  • Positive test results at screening for hepatitis A virus Immunoglobulin M (IgM) antibody (Ab), anti- virus (HCV) Ab, anti- hepatitis D (HDV) Ab or anti- (HIV) Ab
  • Decompensated liver disease (e.g., Class B or C clinical classification or clinical evidence such as ascites or varices)
  • Advanced fibrosis or cirrhosis
  • Suspicion of HCC on liver abdominal ultrasound (all patients to have liver abdominal ultrasound within 6 months prior to baseline)
  • History or other evidence of a medical condition associated with chronic liver disease other than CHB including metabolic liver diseases such as hemochromatosis, Wilson's disease or alpha-1 anti-trypsin deficiency
  • Active substance abuse within 6 months prior to screening
  • Sexually active females of and sexually active males who are not willing to utilize reliable during treatment and for 90 days following the end of treatment
  • Females who are pregnant or who are breastfeeding (females of childbearing potential who have a positive urine or serum pregnancy test result within 24 hours of baseline are excluded)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Peg-IFN-Alfa-2A + Lamivudine or Entecavir

    Participants will receive lamivudine or entecavir alone for 8 weeks followed by peg-IFN-alfa-2A in combination with lamivudine or entecavir for 48 weeks.

    Drug: Entecavir · Drug: Lamivudine · Drug: Pegylated Interferon Alfa-2A

  • No intervention
    Untreated Control Participants

    Untreated control participants will be observed up to 80 weeks.

  • Experimental
    Peg-INF-Alfa-2A Monotherapy

    Participants will receive Peginterferon Alfa 2A subcutaneously once weekly with dosing based on body surface area (BSA) categories for 48 weeks.

    Drug: Pegylated Interferon Alfa-2A

Interventions

  • Participants will receive entecavir, either as a film-coated tablet or oral solution, once daily at a dose of 0.015 milligrams per kilogram (mg/kg) (maximum daily dose of 0.5 mg).

  • Participants will receive lamivudine, either as a film-coated tablet or oral solution, once daily at a dose of 3 mg/kg (maximum daily dose of 100 mg).

  • Participants will receive pegylated interferon-alfa-2A at a body surface area (BSA) based dose of 180 micrograms per 1.73 square meter (mcg/1.73m\^2) BSA.

    Also known as: Pegasys, Peg-IFN-Alfa-2A

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Loss of Hepatitis B Surface Antigen (HBsAg) at 24 Weeks Post-End of Treatment/End of Untreated Observation

    This endpoint is defined as loss of HBsAg at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80). The percentage of responders (response rate) and 95% CI (using the Clopper-Pearson method) for the response rate are presented for each group.

    Time frame: 24 weeks post-treatment/at the end of untreated observation (Week 80)

Secondary outcomes

  1. Percentage of Participants With Loss of HBsAg

    This endpoint is defined as loss of HBsAg at 1 year post-treatment in the treated group. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.

    Time frame: 1 year post-end of treatment (End of treatment = Week 56)

  2. Percentage of Participants With Loss of Hepatitis B Virus Envelope Antigen (HBeAg)

    This endpoint is defined as loss of HBeAg at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-end of treatment in the treated group. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.

    Time frame: 24 weeks post-treatment /end of untreated observation (Week 80), and 1 year post-end of treatment (End of treatment = Week 56)

  3. Percentage of Participants With Seroconversion to Hepatitis B Surface Antibody (Anti-HBs), Defined as Loss of HBsAg and Presence of Anti-HBs

    This endpoint measures the seroconversion to anti-HBs defined as loss of HBsAg and presence of anti-HBs at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-end of treatment in the treated group. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.

    Time frame: 24 weeks post-treatment /end of untreated observation (Week 80), and 1 year post-end of treatment (End of treatment = Week 56)

  4. Percentage of Participants With Seroconversion to Hepatitis B Envelope Antibody (Anti-HBe), Defined as Loss of HBeAg and Presence of Anti-HBe

    This endpoint measures the seroconversion to anti-HBe defined as loss of HBeAg and presence of anti-HBe at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-end of treatment in the treated group. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.

    Time frame: 24 weeks post-treatment /end of untreated observation (Week 80), and 1 year post-end of treatment (End of treatment = Week 56)

  5. Percentage of Participants With Different Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels (Less Than [<] 20,000 International Units Per Milliliter [IU/mL], < 2000 IU/mL, or Undetectable HBV DNA)

    This endpoint measures different HBV DNA levels (\<20000 IU/mL, \<2000 IU/mL and undetectable) measured by PCR or hybridization at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-treatment in the treated group. HBV-DNA undetectable is defined as \<29 IU/mL. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.

    Time frame: 24 weeks post-treatment /end of untreated observation (Week 80), and 1 year post-end of treatment (End of treatment = Week 56)

  6. Change From Baseline in HBV DNA Levels in the Peg-INF-Alfa-2A (Treated) Arm

    This outcome measure presents HBV DNA levels measured at defined time points from baseline in the Peg-INF-Alfa-2A + Lamivudine or Entecavir arm.

    Time frame: Baseline, Week 8, 20, 32, 44, 56, Follow up Week 4 and 24

  7. Change From Baseline in HBV DNA Levels in the Untreated Control Participants

    This outcome measure presents HBV DNA levels measured at defined time points from baseline in the Untreated Control arm.

    Time frame: Baseline, Week 32, 56 and end of untreated observation (Week 80)

  8. Percentage of Participants With Combined Response for HBeAg Seroconversion (Defined as Loss of HBeAg and Presence of Anti-HBe) and HBV DNA Levels <20,000 IU/mL

    This endpoint measures the combined response for HBeAg Seroconversion and HBV DNA Levels \<20,000 IU/mL at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-end of treatment in the treated group. The HBeAg is defined as loss of HBeAg and presence of anti-HBe. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.

    Time frame: 24 weeks post-treatment /end of untreated observation (Week 80), and 1 year post-end of treatment (End of treatment = Week 56)

  9. Percentage of Participants With Combined Response for HBeAg Seroconversion (Defined as Loss of HBeAg and Presence of Anti-HBe) and HBV DNA Levels <2000 IU/mL

    This endpoint measures the combined response for HBeAg Seroconversion and HBV DNA Levels \<2000 IU/mL at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-end of treatment in the treated group. The HBeAg is defined as loss of HBeAg and presence of anti-HBe. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.

    Time frame: 24 weeks post-treatment /end of untreated observation (Week 80), and 1 year post-end of treatment (End of treatment = Week 56)

  10. Percentage of Participants With Adverse Events (AEs)

    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

    Time frame: Baseline up to 24 weeks post-treatment/end of untreated observation (Week 80)

  11. Percentage of Participants With AEs Leading to Dose Modification or Interruption

    This endpoint measures AEs and lab abnormalities leading to dose interruption or dose modification. Does modification included dose reduced, dose increased or drug interrupted. Adverse events included laboratory abnormalities reported as adverse events.

    Time frame: Baseline up to 24 weeks post-end of treatment

  12. Serum Concentration of Peg-INF-Alfa-2A

    The serum concentration of Peg-INF-Alfa-2A was measured in picogram/milliliter.

    Time frame: At Weeks 12, 16, 20, 32, 44, 56

07

Results

Posted Aug 24, 2020
Limitations and caveats
In accordance with the recommendation from the DSMB, enrollment was stopped due to low efficacy and a changed benefit risk assessment. Enrolled participants were allowed to complete treatment and were followed up for 1 year after the end of treatment

Participant flow

The study began as a single-site, three arm IST and was subsequently adapted as a multi-center, two arm study, conducted at 22 sites in Malaysia, Taiwan, Australia, Belgium, Germany, United Kingdom, Italy, Romania, Russian Federation, Turkey, Ukraine and the U.S. Enrolment was stopped prematurely, at which time 62 participants had been enrolled.

Participant flow — Overall Study
MilestonePeg-IFN-Alfa-2A + Lamivudine or EntecavirUntreated Control ParticipantsPeg-INF-Alfa-2A Monotherapy
Started26333
Completed23253
Not completed380
Withdrew: Physician decision100
Withdrew: Withdrawal by subject280

Outcome measures

PrimaryPercentage of Participants With Loss of Hepatitis B Surface Antigen (HBsAg) at 24 Weeks Post-End of Treatment/End of Untreated Observation

This endpoint is defined as loss of HBsAg at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80). The percentage of responders (response rate) and 95% CI (using the Clopper-Pearson method) for the response rate are presented for each group.

Time frame:
24 weeks post-treatment/at the end of untreated observation (Week 80)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Loss of Hepatitis B Surface Antigen (HBsAg) at 24 Weeks Post-End of Treatment/End of Untreated Observation
Percentage of ParticipantsPeg-IFN-Alfa-2A + Lamivudine or EntecavirUntreated Control Participants
Percentage of Participants With Loss of Hepatitis B Surface Antigen (HBsAg) at 24 Weeks Post-End of Treatment/End of Untreated Observation3.8 (0.10 to 19.64)0 (0.00 to 10.58)
SecondaryPercentage of Participants With Loss of HBsAg

This endpoint is defined as loss of HBsAg at 1 year post-treatment in the treated group. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.

Time frame:
1 year post-end of treatment (End of treatment = Week 56)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Loss of HBsAg
Percentage of ParticipantsPeg-IFN-Alfa-2A + Lamivudine or Entecavir
Percentage of Participants With Loss of HBsAg3.8 (0.10 to 19.64)
SecondaryPercentage of Participants With Loss of Hepatitis B Virus Envelope Antigen (HBeAg)

This endpoint is defined as loss of HBeAg at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-end of treatment in the treated group. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.

Time frame:
24 weeks post-treatment /end of untreated observation (Week 80), and 1 year post-end of treatment (End of treatment = Week 56)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Loss of Hepatitis B Virus Envelope Antigen (HBeAg)
Percentage of ParticipantsPeg-IFN-Alfa-2A + Lamivudine or EntecavirUntreated Control Participants
24 Weeks post-treatment/Week 803.8 (0.10 to 19.64)12.1 (3.40 to 28.20)
1 year post-end of treatment11.5 (2.45 to 30.15)—
SecondaryPercentage of Participants With Seroconversion to Hepatitis B Surface Antibody (Anti-HBs), Defined as Loss of HBsAg and Presence of Anti-HBs

This endpoint measures the seroconversion to anti-HBs defined as loss of HBsAg and presence of anti-HBs at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-end of treatment in the treated group. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.

Time frame:
24 weeks post-treatment /end of untreated observation (Week 80), and 1 year post-end of treatment (End of treatment = Week 56)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Seroconversion to Hepatitis B Surface Antibody (Anti-HBs), Defined as Loss of HBsAg and Presence of Anti-HBs
Percentage of ParticipantsPeg-IFN-Alfa-2A + Lamivudine or EntecavirUntreated Control Participants
24 Weeks post-treatment/Week 803.8 (0.10 to 19.64)0.0 (0.00 to 10.58)
1 year post-end of treatment3.8 (0.10 to 19.64)—
SecondaryPercentage of Participants With Seroconversion to Hepatitis B Envelope Antibody (Anti-HBe), Defined as Loss of HBeAg and Presence of Anti-HBe

This endpoint measures the seroconversion to anti-HBe defined as loss of HBeAg and presence of anti-HBe at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-end of treatment in the treated group. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.

Time frame:
24 weeks post-treatment /end of untreated observation (Week 80), and 1 year post-end of treatment (End of treatment = Week 56)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Seroconversion to Hepatitis B Envelope Antibody (Anti-HBe), Defined as Loss of HBeAg and Presence of Anti-HBe
Percentage of ParticipantsPeg-IFN-Alfa-2A + Lamivudine or EntecavirUntreated Control Participants
24 Weeks post-treatment/Week 800.0 (0.00 to 13.23)9.1 (1.92 to 24.33)
1 year post-end of treatment7.7 (0.95 to 25.13)—
SecondaryPercentage of Participants With Different Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels (Less Than [<] 20,000 International Units Per Milliliter [IU/mL], < 2000 IU/mL, or Undetectable HBV DNA)

This endpoint measures different HBV DNA levels (\<20000 IU/mL, \<2000 IU/mL and undetectable) measured by PCR or hybridization at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-treatment in the treated group. HBV-DNA undetectable is defined as \<29 IU/mL. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.

Time frame:
24 weeks post-treatment /end of untreated observation (Week 80), and 1 year post-end of treatment (End of treatment = Week 56)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Different Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels (Less Than [<] 20,000 International Units Per Milliliter [IU/mL], < 2000 IU/mL, or Undetectable HBV DNA)
Percentage of ParticipantsPeg-IFN-Alfa-2A + Lamivudine or EntecavirUntreated Control Participants
HBV-DNA <20000 IU/mL at follow up Week 24/Week 807.7 (0.95 to 25.13)12.1 (3.40 to 28.20)
HBV-DNA <2000 IU/mL at follow up Week 24/Week 807.7 (0.95 to 25.13)12.1 (3.40 to 28.20)
HBV-DNA Undetectable at follow up Week 24/Week 800.0 (0.00 to 13.23)6.1 (0.74 to 20.23)
HBV-DNA <20000 IU/mL 1 year post-end of treatment15.4 (4.36 to 34.87)—
HBV-DNA <2000 IU/mL 1 year post-end of treatment7.7 (0.95 to 25.13)—
HBV-DNA Undetectable 1 year post-end of treatment0.0 (0.00 to 13.23)—
SecondaryChange From Baseline in HBV DNA Levels in the Peg-INF-Alfa-2A (Treated) Arm

This outcome measure presents HBV DNA levels measured at defined time points from baseline in the Peg-INF-Alfa-2A + Lamivudine or Entecavir arm.

Time frame:
Baseline, Week 8, 20, 32, 44, 56, Follow up Week 4 and 24
Reported as:
Mean · log10 IU/mL
Change From Baseline in HBV DNA Levels in the Peg-INF-Alfa-2A (Treated) Arm
log10 IU/mLPeg-IFN-Alfa-2A + Lamivudine or Entecavir
Baseline8.02 ± 0.93
Week 84.74 ± 1.01
Week 203.54 ± 0.81
Week 322.56 ± 0.84
Week 442.15 ± 0.70
Week 562.21 ± 0.90
Fu Week 44.34 ± 2.65
Fu Week 247.31 ± 1.99
SecondaryChange From Baseline in HBV DNA Levels in the Untreated Control Participants

This outcome measure presents HBV DNA levels measured at defined time points from baseline in the Untreated Control arm.

Time frame:
Baseline, Week 32, 56 and end of untreated observation (Week 80)
Reported as:
Mean · log10 IU/mL
Change From Baseline in HBV DNA Levels in the Untreated Control Participants
log10 IU/mLUntreated Control Participants
Baseline8.22 ± 1.07
Week 328.29 ± 0.97
Week 567.57 ± 1.96
Week 807.24 ± 2.58
SecondaryPercentage of Participants With Combined Response for HBeAg Seroconversion (Defined as Loss of HBeAg and Presence of Anti-HBe) and HBV DNA Levels <20,000 IU/mL

This endpoint measures the combined response for HBeAg Seroconversion and HBV DNA Levels \<20,000 IU/mL at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-end of treatment in the treated group. The HBeAg is defined as loss of HBeAg and presence of anti-HBe. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.

Time frame:
24 weeks post-treatment /end of untreated observation (Week 80), and 1 year post-end of treatment (End of treatment = Week 56)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Combined Response for HBeAg Seroconversion (Defined as Loss of HBeAg and Presence of Anti-HBe) and HBV DNA Levels <20,000 IU/mL
Percentage of ParticipantsPeg-IFN-Alfa-2A + Lamivudine or EntecavirUntreated Control Participants
24 Weeks post-treatment/Week 800.0 (0.00 to 13.23)9.1 (1.92 to 24.33)
1 year post-end of treatment7.7 (0.95 to 25.13)—
SecondaryPercentage of Participants With Combined Response for HBeAg Seroconversion (Defined as Loss of HBeAg and Presence of Anti-HBe) and HBV DNA Levels <2000 IU/mL

This endpoint measures the combined response for HBeAg Seroconversion and HBV DNA Levels \<2000 IU/mL at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-end of treatment in the treated group. The HBeAg is defined as loss of HBeAg and presence of anti-HBe. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.

Time frame:
24 weeks post-treatment /end of untreated observation (Week 80), and 1 year post-end of treatment (End of treatment = Week 56)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Combined Response for HBeAg Seroconversion (Defined as Loss of HBeAg and Presence of Anti-HBe) and HBV DNA Levels <2000 IU/mL
Percentage of ParticipantsPeg-IFN-Alfa-2A + Lamivudine or EntecavirUntreated Control Participants
24 Weeks post-treatment/Week 800.0 (0.00 to 13.23)9.1 (1.92 to 24.33)
1 year post-end of treatment7.7 (0.95 to 25.13)—
SecondaryPercentage of Participants With Adverse Events (AEs)

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

Time frame:
Baseline up to 24 weeks post-treatment/end of untreated observation (Week 80)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Adverse Events (AEs)
Percentage of ParticipantsPeg-IFN-Alfa-2A + Lamivudine or EntecavirUntreated Control Participants
With at least one Non-Serious AE92.345.5
With at least one Serious Adverse Event (SAE)03.0
SecondaryPercentage of Participants With AEs Leading to Dose Modification or Interruption

This endpoint measures AEs and lab abnormalities leading to dose interruption or dose modification. Does modification included dose reduced, dose increased or drug interrupted. Adverse events included laboratory abnormalities reported as adverse events.

Time frame:
Baseline up to 24 weeks post-end of treatment
Reported as:
Number · Percentage of Participants
Percentage of Participants With AEs Leading to Dose Modification or Interruption
Percentage of ParticipantsPeg-IFN-Alfa-2A + Lamivudine or Entecavir
Percentage of Participants With AEs Leading to Dose Modification or Interruption23.0
SecondarySerum Concentration of Peg-INF-Alfa-2A

The serum concentration of Peg-INF-Alfa-2A was measured in picogram/milliliter.

Time frame:
At Weeks 12, 16, 20, 32, 44, 56
Reported as:
Mean · pg/mL
Serum Concentration of Peg-INF-Alfa-2A
pg/mLPeg-IFN-Alfa-2A + Lamivudine or Entecavir
Week 12 Predose8430 ± 6090
Week 16 Predose16300 ± 10100
Week 20 Predose13800 ± 8740
Week 32 Predose14900 ± 7710
Week 32 24-48h Post-dose22700 ± 6070
Week 32 72-96h Post-dose23000 ± 4900
Week 32 168h Post-dose19300 ± 5880
Week 44 Predose21900 ± 14200
Week 56 Predose25400 ± 13100

Adverse events

Collected over From Baseline up to 1 year post-end of treatment in the treated arm; From Baseline to end of untreated observation (Week 80) in the untreated group [up to clinical cut-off date 29 Jan 2020]. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Peg-IFN-Alfa-2A + Lamivudine or Entecavir0/26 (0%)0/26 (0%)21/26 (80.8%)
Untreated Control Participants0/33 (0%)1/33 (3%)10/33 (30.3%)
Peg-INF-Alfa-2A Monotherapy0/3 (0%)0/3 (0%)—
Most frequent serious events
Most frequent serious events
EventPeg-IFN-Alfa-2A + Lamivudine or EntecavirUntreated Control ParticipantsPeg-INF-Alfa-2A Monotherapy
PHARYNGITISInfections and infestations0/261/330/3
DEHYDRATIONMetabolism and nutrition disorders0/261/330/3
Most frequent other events
Showing 10 of 26
Most frequent other events
EventPeg-IFN-Alfa-2A + Lamivudine or EntecavirUntreated Control ParticipantsPeg-INF-Alfa-2A Monotherapy
HEADACHENervous system disorders14/260/33—
PYREXIAGeneral disorders11/260/33—
FATIGUEGeneral disorders5/260/33—
NAUSEAGastrointestinal disorders4/261/33—
ABDOMINAL PAIN UPPERGastrointestinal disorders3/263/33—
VOMITINGGastrointestinal disorders3/261/33—
PAINGeneral disorders3/260/33—
NASOPHARYNGITISInfections and infestations3/261/33—
DIZZINESSNervous system disorders3/260/33—
EPISTAXISRespiratory, thoracic and mediastinal disorders3/261/33—

Baseline characteristics

Due to the low participant number (n=3) in the Peg-INF-Alfa-2A Monotherapy arm, data is not presented in this summary for this arm to avoid participant re-identification as well as in consideration of any summary statistics would be misleading, therefore the three participants were presented in listings in the study report.

Age, Continuous
Age, Continuous(Years)Peg-IFN-Alfa-2A + Lamivudine or EntecavirUntreated Control ParticipantsPeg-INF-Alfa-2A MonotherapyTotal
Mean11.9 ± 3.210.9 ± 3.7—11.3 ± 3.5
Sex: Female, Male
Sex: Female, Male(Participants)Peg-IFN-Alfa-2A + Lamivudine or EntecavirUntreated Control ParticipantsPeg-INF-Alfa-2A MonotherapyTotal
Female1614—30
Male1019—29
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Peg-IFN-Alfa-2A + Lamivudine or EntecavirUntreated Control ParticipantsPeg-INF-Alfa-2A MonotherapyTotal
Hispanic or Latino10—1
Not Hispanic or Latino2533—58
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Peg-IFN-Alfa-2A + Lamivudine or EntecavirUntreated Control ParticipantsPeg-INF-Alfa-2A MonotherapyTotal
Asian1111—22
Black or African American42—6
Multiple20—2
Other03—3
White917—26
08

Study locations

25 sites
  • Children's Mercy Hosp Clinics
    Kansas City, Missouri 64108, United States
  • Columbia University
    New York, New York 10032-3725, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Womens and Childrens Hospital; Department of Gastroenterology
    North Adelaide, South Australia 5006, Australia
  • Cliniques Universitaires St-Luc
    Bruxelles, 1200, Belgium
  • UZ Gent
    Gent, 9000, Belgium
  • Universitätsklinikum Essen; Klinik für Kinder- und Jugendmedizin Pädiatrie II
    Essen, 45122, Germany
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Zentrum für Kinder- und Jugendmedizin
    Mainz, 55131, Germany
  • Dr. von Haunerschen Kinderspital, Kinderchirurgische Klinik und Poliklinik
    München, 80337, Germany
  • HELIOS Klinikum Wuppertal, Zentrum für Kinder- und Jugendmedizin, Universität Witten-Herdecke
    Wuppertal, 42283, Germany
  • Azienda Ospedaliero-Universitaria Policlinico S. Orsola Malpighi; U.O. Malattie Infettive
    Bologna, Emilia-Romagna 40138, Italy
  • University Malaya Medical Center; Department of Paediatrics
    Kuala Lumpur, 59100, Malaysia
  • Grigore Alexandrescu Emergency Clinical Hospital for Children
    Bucharest, 011743, Romania
  • FSI Scientific research Institute of children's infections
    Saint Petersburg, 197022, Russian Federation
  • MC Gepatolog
    Samara, 443100, Russian Federation
  • Chang-Gung Memorial Hospital-Linkou; Division of Pediatric Gastroenterology, Dept Pediatrics
    Taoyuan County, 333, Taiwan
  • Cukurova University Medical School Department of Pediatrics; Pediatric Infectious Diseases
    Adana, 01330, Turkey
  • Ankara University School of Medicine, Pediatrics Department; Pediatric Gastroenterology
    Ankara, 06100, Turkey
  • Hacettepe Uni , School of Medicine; Gastroenterology
    Ankara, 06100, Turkey
  • Gazi Universitesi Tip Fakultesi Pediyatri Anabilim Dalı; Pediyatrik Gastroenteroloji
    Ankara, 06500, Turkey
  • SI Institute of the pediatrics, obstetrics and gynecology
    Kyiv, 04050, Ukraine
  • Birmingham Children'S Hopsital; Liver Unit
    Birmingham, B4 6NH, United Kingdom
  • Leeds Teaching Hospitals NHS Trust
    Leeds, LS9 7AU, United Kingdom
  • Kings College Hospital NHS Foundation Trust
    London, SE5 9RS, United Kingdom
  • North Manchester General Hospital
    Manchester, M8 5RB, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Jan 2020, 67 months.

Results were first posted in Aug 2020, 6 months after primary completion.

Of 24 phase 3 interventional studies under Hepatitis B, Chronic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's 67 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2014
First posted
Oct 13, 2014
StartActual
Jun 16, 2014
Primary completionActual
Jan 29, 2020
CompletionActual
Jan 29, 2020
Results first posted
Aug 24, 2020
Last update
Aug 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02263079
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 13, 2014
Start date
Jun 16, 2014
Primary completion
Jan 29, 2020
Completion
Jan 29, 2020
Results posted
Aug 24, 2020
Last update
Aug 24, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Entecavir · Lamivudine · Peginterferon alfa-2a

Start the discussion